title: Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.
abstract: BACKGROUND
  Generic substitution is one mechanism of curtailing prescription drug expenditures. Limited information is available about the potential savings associated with generic substitution.
  
  
  OBJECTIVE
  To estimate the potential savings associated with broad substitution of generic drugs.
  
  
  METHODS
  Cross-sectional, nationally representative survey of noninstitutionalized adults.
  
  
  METHODS
  United States.
  
  
  METHODS
  Adults included in the Medical Expenditure Panel Survey Household Component, 1997-2000.
  
  
  METHODS
  Use of a multisource drug (that is, a drug available in a brand-name and > or =1 generic formulation) or a generic drug and the potential cost savings associated with broad generic substitution for all multisource products.
  
  
  RESULTS
  Fifty-six percent of all outpatient drugs were multisource products, accounting for 41% of total outpatient drug expenditures. Of these multisource drugs, 61% were dispensed as a generic. If a generic had been substituted for all corresponding brand-name outpatient drugs in 2000, the median annual savings in drug expenditures per person would have been 45.89 dollars (interquartile range, 10.35 dollars to 158.06) for adults younger than 65 years of age and 78.05 dollars (interquartile range, 19.94 dollars to 241.72 dollars) for adults at least 65 years of age. In these age groups, the national savings would have been 5.9 billion dollars (95% CI, 5.5 billion dollars to 6.2 billion dollars) and 2.9 billion dollars (CI, 2.6 billion dollars to 3.1 billion dollars), respectively, representing approximately 11% of drug expenditures.
  
  
  CONCLUSIONS
  Specific information about an individual's formulary was not available, so the authors could not estimate how much of the potential savings would benefit an individual or his or her health plan.
  
  
  CONCLUSIONS
  Although broad substitution of generic drugs would affect only a modest percentage of drug expenditures, it could result in substantial absolute savings.
authors.affiliation: Brigham and Women's Hospital, Division of General Medicine and Primary Care, Boston, Massachusetts 02120, USA. jhaas@partners.org
authors.forename: Jennifer S
authors.initials: JS
authors.lastname: Haas
authors.forename: Kathryn A
authors.initials: KA
authors.lastname: Phillips
authors.forename: Eric P
authors.initials: EP
authors.lastname: Gerstenberger
authors.forename: Andrew C
authors.initials: AC
authors.lastname: Seger
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017046:Cost Savings; D003430:Cross-Sectional Studies; D016527:Drug Costs; D011307:Drug Prescriptions / Q000191:economics*; D016568:Drugs, Generic / Q000191:economics*; D005260:Female; D006801:Humans; D008297:Male; D006278:Medicare / Q000191:economics; D008875:Middle Aged; D011306:Prescription Fees; D014481:United States
chemical_list: D016568:Drugs, Generic